Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 10/20 | 0.46 |
| ▸ | PDE1A | P54750 | 1/20 | 0.34 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.34 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6080948 | 1.00 | CRHR1 (0.46) | CRHR1PDE1APDE1BPDE1CP2RX7 | |
| SCHEMBL6080953 | 1.00 | CRHR1 (0.46) | CRHR1PDE1APDE1BPDE1CP2RX7 | |
| SCHEMBL5778772 | 0.93 | CRHR1 (0.49) | CRHR1PDE1APDE1BPDE1CP2RX7 | |
| SCHEMBL5782147 | 0.90 | CRHR1 (0.47) | CRHR1PDE1APDE1BPDE1CP2RX7 | |
| SCHEMBL6081317 | 0.89 | CRHR1 (0.47) | CRHR1PDE1APDE1BPDE1CP2RX7 | |
| SCHEMBL5750253 | 0.89 | CRHR1 (0.47) | CRHR1PDE1APDE1BPDE1CP2RX7 | |
| SCHEMBL5782552 | 0.89 | CRHR1 (0.47) | CRHR1PDE1APDE1BPDE1CP2RX7 | |
| SCHEMBL6081426 | 0.87 | CRHR1 (0.49) | CRHR1PDE1APDE1BPDE1CP2RX7 | |
| SCHEMBL5776289 | 0.86 | CRHR1 (0.44) | CRHR1PDE1APDE1BPDE1CP2RX7 | |
| SCHEMBL5778979 | 0.85 | CRHR1 (0.43) | CRHR1PDE1APDE1BPDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113379-A1 | Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands | AVENTIS PHARMACEUTICALS, INC. | 2005-05-26 | — | — | US | claimed |
| US-20060199823-A1 | Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands | NEUROGEN CORPORATION (US) | 2006-09-07 | — | — | US | disclosed |
| US-20050113379-A1 | Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands | AVENTIS PHARMACEUTICALS, INC. | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199823-A1 | Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands | CRHR1, CRHR2, HTR5A | CRHR1 1/4885PDE1A 520/4885PDE1B 472/4885 |
| US-20050113379-A1 | Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands | CRHR1, CRHR2, HTR5A | CRHR1 1/4885PDE1A 520/4885PDE1B 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.